W
Weizhen Liu
Researcher at Zhengzhou University
Publications - 12
Citations - 523
Weizhen Liu is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Neuroprotection & MPTP. The author has an hindex of 8, co-authored 12 publications receiving 375 citations. Previous affiliations of Weizhen Liu include Shanxi Medical University.
Papers
More filters
Journal ArticleDOI
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Weizhen Liu,Jaishree Jalewa,Mohit K. Sharma,Guanglai Li,Lin Li,Christian Hölscher,Christian Hölscher +6 more
TL;DR: Both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
Journal ArticleDOI
Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
TL;DR: The results showed that treatment with TA significantly reversed the memory deficit in the APP/PS1 mice in a spatial water maze test and showed that novel TAs are a promising lead for the design of future treatment strategies in AD.
Journal ArticleDOI
Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
TL;DR: D-Ala2-GIP-glu-PAL promotes cell survival of dopaminergic neuron in the SNpc by activating the cAMP/PKA/CREB growth factor second messenger pathway that also inhibits apoptosis.
Journal ArticleDOI
Neuroprotective effects of geniposide on Alzheimer's disease pathology.
TL;DR: The possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD are reviewed: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway.
Journal ArticleDOI
D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation.
TL;DR: Chronic treatment with D‐Ala2‐GIP‐glu‐PAL inhibits MPTP ‐induced Parkinsonism‐like motor disorders in mice, and that the drug prevents dopaminergic neuronal loss in the substantia nigra pars compacta (SNpc).